YD Bio (NASDAQ:YDES) Stock Rating Upgraded by Wall Street Zen

YD Bio (NASDAQ:YDES) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

YD Bio Price Performance

NASDAQ YDES opened at $5.73 on Friday. The firm’s fifty day simple moving average is $3.32 and its two-hundred day simple moving average is $4.17. YD Bio has a 12-month low of $1.70 and a 12-month high of $22.00.

YD Bio (NASDAQ:YDES) last issued its quarterly earnings data on Tuesday, September 1st. The biotechnology company reported $0.05 EPS for the quarter. The business had revenue of $0.42 million for the quarter.

Institutional Investors Weigh In On YD Bio

An institutional investor recently raised its position in YD Bio stock. Cypress Capital Management LLC WY boosted its stake in shares of YD Bio Limited (NASDAQ:YDES) by 9.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 33,690 shares of the biotechnology company’s stock after purchasing an additional 3,000 shares during the period. Cypress Capital Management LLC WY’s holdings in YD Bio were worth $76,000 at the end of the most recent reporting period.

YD Bio Company Profile

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.